Pfizer Inc. (PFE) Announces Positive Results From its Phase 3 HER2CLIMB-05 Trial

Group 1 - Pfizer Inc. announced positive results from its Phase 3 HER2CLIMB-05 trial, which tested the kinase inhibitor TUKYSA in combination therapy for HER2+ metastatic breast cancer, showing significant improvement in progression-free survival compared to placebo [1][2] - The HER2+ breast cancer type is challenging, with many patients experiencing disease progression despite existing treatments, but the trial results indicate that TUKYSA can effectively halt disease progression while maintaining a healthy safety profile [2] Group 2 - Pfizer Inc. is a global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing medicines [3]